Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-01-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于继续使用部分闲置募集资金临时性补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shandong Ruikang Pharmaceutical Co., Ltd. regarding the continued use of idle raised funds to temporarily supplement working capital. It includes extensive information about previous fundraising activities, the use and return of funds, board and supervisory approvals, independent directors' opinions, and the sponsor's opinions. The content focuses on the company's capital management and the use of raised funds rather than presenting financial statements or earnings data. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a brief announcement of voting results or a proxy statement. It is a regulatory announcement about capital usage and compliance with fundraising regulations. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8273 characters) and detailed content support this classification with high confidence.
2016-01-11 Chinese
国金证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Guojin Securities Co., Ltd. regarding Shandong Ruikang Pharmaceutical Co., Ltd.'s use of part of idle raised funds to temporarily supplement working capital. It includes historical approvals, amounts, usage periods, and compliance with regulatory requirements. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a formal verification or audit opinion related to the use of raised funds, which aligns with the category of Audit Report / Information (AR). The document length is about 4994 characters, which is sufficient to contain substantive content rather than a brief announcement. There is no indication that this is a report publication announcement or a regulatory filing. Therefore, the best classification is AR (Audit Report / Information). FY 2016
2016-01-11 Chinese
关于非公开发行股票摊薄即期回报对公司主要财务指标的影响及公司采取措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding the impact of a non-public stock issuance on immediate earnings dilution and the company's measures to address this. It includes detailed financial assumptions, projections of earnings per share and return on equity before and after the issuance, risk warnings about dilution, and descriptions of how the company plans to use the raised funds and improve future returns. The document references regulatory guidelines from the China Securities Regulatory Commission and includes commitments from directors and major shareholders about the implementation of these measures. The content focuses on the impact of a capital raising event (non-public stock issuance) on financial metrics and investor returns, along with risk disclosures and mitigation plans. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising activities and their financial impact. The document is substantive and not merely an announcement of a report or a certification, and it is not a full annual or interim report. Therefore, the appropriate classification is CAP with high confidence.
2016-01-11 Chinese
关于非公开发行股票相关承诺事项的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding commitments related to a non-public issuance of shares. It includes statements about shareholding, commitments by controlling shareholders and management, and compliance with regulatory requirements from the China Securities Regulatory Commission. The document is relatively short (1123 characters) and focuses on disclosure of commitments related to a capital raising event (non-public share issuance). It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an announcement related to capital issuance and associated commitments, fitting the category of Capital/Financing Update (CAP).
2016-01-11 Chinese
关于收到《中国证监会行政许可项目审查反馈意见通知书》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shandong Ruikang Pharmaceutical Co., Ltd. regarding receipt of a feedback notice from the China Securities Regulatory Commission (CSRC) about the review of a non-public share issuance application. It states that the company must respond within 30 days and that approval is still uncertain. The document is short (576 characters) and serves as a regulatory update on the status of a financing approval process, not the actual financing report or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP).
2016-01-05 Chinese
关于实际控制人股权质押解除公告
Major Shareholding Notification Classification · 95% confidence The document is a short announcement regarding the release of a pledge on shares held by the actual controller of the company. It details the number of shares released from pledge and the current pledge status. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. This fits the category of a Major Shareholding Notification, as it concerns changes in significant share ownership or share pledge status by a major shareholder.
2015-12-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.